Genomtec S.A.

Board/Management Information • Nov 3, 2021

Planned acceleration of the Genomtec ID platform commercializationprocess.The Management Board of Genomtec S.A. ("Company","Issuer") hereby informs that today, i.e. on 3 November 2021,considering the prospective development of a targeted market where theIssuer operates, i.e. the diagnostic segment of rapid POC testing,reflected into Company's strategic developmental goals and publiclyannounced via Company's Information Documents, the Issuer has commencedan analysis on feasibility of accelerated commercialization of theGenomtec® ID platform.The analysis will include a selectionof optimal solutions supporting the strategic Company's development,primarily, determining the prime time for market entry of the Genomtec®ID platform, inclusively of its acceleration with respect to thecurrently announced plan. As part of the analysis, various scenariosfast-tracking Company's development will be deliberated, includingpossible use of existing regulations enabling faster devicecertification and, consequently, faster market authorization generatingsales' revenue. One of the analyzed variables will include commercialsale activities for Genomtec® ID to be conducted by the Company,leveraging for this purpose trading partners and determination of anappropriate time for technology out-licensing or sale its acquisition.The activities are aimed at improving Company's operational scale-up,utilizing of market and legal conditions and the Company's know-how.TheIssuer will inform about any future important stages of the process incurrent reports.